Acelyrin (SLRN) said late Thursday it has received an unsolicited indication of interest from Tang Capital Partners-backed Concentra Biosciences to acquire all of its outstanding shares for $3.00 per share in cash, plus a contingent value right to receive 80% of net proceeds from any out-license or disposition of its development programs or intellectual property.
Acelyrin said it agreed Feb. 6 to an all-stock merger with Alumis (ALMS) in a deal expected to close in Q2.
The company said its board is committed to acting in the interests of shareholders and will make a further announcement on the matter "in due course."
Shares of Acelyrin rose more than 12% in recent premarket activity Friday.
Price: 2.45, Change: +0.28, Percent Change: +12.90
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。